58 Biggest Movers From Yesterday

Gainers

  • Sienna Biopharmaceuticals Inc SNNA jumped 77.5% to $0.2020 on seemingly no company-specific news.
  • Dova Pharmaceuticals, Inc. DOVA shares gained 38.4% to close at $27.95 in reaction to a buyout deal. Dova said Monday it has entered into an agreement to be bought by Swedish Orphan Biovitrum, or SOBI, for $27.50 per share in cash, along with one non-tradeable contingent value right, or CVR, that entitles Dova shareholders to receive an additional $1.50 per share in cash upon regulatory approval of Doptelet.
  • Enochian Biosciences Inc. ENOB rose 29.4% to close at $5.50.
  • GTT Communications, Inc. GTT gained 20.8% to close at $9.42 as a potential rebound after the stock fell roughly 20% since last Thursday when the stock could not break the $10 resistance level.
  • Capricor Therapeutics, Inc. CAPR rose 20.1% to close at $3.70.
  • China Customer Relations Centers, Inc. CCRC gained 17.9% to close at $15.99.
  • Verrica Pharmaceuticals Inc. VRCA rose 17.9% to close at $14.76.
  • Sundial Growers Inc. SNDL gained 16.7% to close at $4.795.
  • Thor Industries, Inc. THO gained 15.8% to close at $56.64 after the company reported better-than-expected Q4 EPS results.
  • The RealReal, Inc. REAL climbed 15.6% to close at $22.36.
  • Jiayin Group Inc. JFIN gained 14.8% to close at $16.69.
  • Akero Therapeutics, Inc. AKRO climbed 14.7% to close at $22.75.
  • Otonomy, Inc. OTIC gained 12.7% to close at $2.39.
  • Seattle Genetics, Inc. SGEN shares rose 12.4% to close at $85.40 after Piper Jaffray maintained an Overweight rating on the stock and raised the price target from $75 to $95. Piper Jaffray raised the price target after Seattle Genetics presented compelling initial data from the EV-103 study, which compares favorably to the current standard of care. It also sees the potential for further upside from additional UBS opportunities.
  • SpringWorks Therapeutics, Inc. SWTX gained 12.2% to close at $21.68.
  • Contango Oil & Gas Company MCF rose 12.1% to close at $2.78.
  • Fastly, Inc. FSLY gained 11% to close at $24.00.
  • Idera Pharmaceuticals, Inc. IDRA rose 10.7% to close at $2.89.
  • Patrick Industries, Inc. PATK climbed 10.1% to close at $42.88. Patrick Industries completed the acquisition of G.G. Schmitt & Sons, Inc.
  • Atreca, Inc. BCEL gained 10.1% to close at $12.24.
  • Danaos Corporation DAC climbed 9.8% to close at $9.00.
  • ATIF Holdings Limited ATIF gained 9% to close at $3.02.
  • Bed Bath & Beyond Inc. BBBY rose 7.6% to close at $10.64. Wedbush upgraded Bed Bath & Beyond from Neutral to Outperform and raised the price target from $14 to $16.
  • REGENXBIO Inc. RGNX climbed 6.8% to close at $35.60.
  • GreenSky, Inc. GSKY gained 6.7% to close at $6.84.
  • Cerus Corporation CERS gained 6.1% to close at $5.16.

 

Check out these big penny stock gainers and losers

 

Losers

  • Ocugen Inc OCGN shares dipped 70.4% to close at $2.88 on Monday. Ocugen announced the completion of its merger with Histogenics Corporation. Ocugen and CanSinoBIO reported a strategic partnership for gene therapy co-development and manufacturing.
  • G1 Therapeutics, Inc. GTHX fell 32.9% to close at $22.78. G1 Therapeutics presented updated data at ESMO 2019 from randomized Phase 2 trial of trilaciclib in combination with chemotherapy in metastatic triple-negative breast cancer demonstrating significant improvement in overall survival at ESMO 2019.
  • Adamas Pharmaceuticals, Inc. ADMS fell 23.3% to close at $5.11. Bank of America downgraded Adamas Pharmaceuticals from Neutral to Underperform.
  • NanoViricides, Inc. NNVC dipped 21.5% to close at $2.04. NanoViricides filed to raise up to $18.3 million.
  • Provention Bio, Inc. PRVB fell 16% to close at $6.82.
  • BENITEC BIOPHAR/S ADR BNTC dropped 15.2% to close at $0.7107 after reporting a $2.25 million registered direct offering.
  • Lexicon Pharmaceuticals, Inc. LXRX dropped 12.4% to close at $3.01, potentially following a bearish blog post alleging the company does not have enough cash to finish ongoing trials.
  • Cal-Maine Foods, Inc. CALM fell 12% to close at $39.96 after the company reported worse-than-expected Q1 EPS and sales results.
  • Viveve Medical, Inc. VIVE dropped 12% to close at $4.41.
  • Globus Maritime Ltd GLBS shares fell 11.6% to close at $2.05. Globus Maritime reported a Q2 loss of $0.74 per share, versus a year-ago loss of $0.29 per share. Its sales slipped to $3.4 million from $4.194 million.
  • FTS International, Inc. FTSI dropped 11.1% to close at $2.24.
  • ImmunoGen, Inc. IMGN dipped 11% to close at $2.42 after the company presented data from its unsuccessful FORWARD I study of mirvetuximab. Piper Jaffray analysts noted a change in methodology may have led to the enrollment of patients who did not meet intended threshold.
  • Novavax, Inc. NVAX dropped 10.9% to close at $5.02.
  • Arcus Biosciences, Inc. RCUS shares declined 10.6% to close at $9.10.
  • Pier 1 Imports, Inc. PIR dropped 10.6% to close at $9.72.
  • SunCoke Energy, Inc. SXC dipped 10.5% to close at $5.64.
  • Teekay LNG Partners L.P. TGP shares fell 9.8% to close at $13.65. Teekay Companies will postpone its investor day originally scheduled on Oct 2 to focus on Teekay LNG.
  • Sears Hometown and Outlet Stores, Inc. SHOS dipped 9.7% to close at $3.44.
  • BioCryst Pharmaceuticals, Inc. BCRX fell 9.6% to close at $2.8650.
  • Stage Stores, Inc. SSI dipped 9.6% to close at $1.88.
  • Big 5 Sporting Goods Corporation BGFV fell 9.6% to close at $2.08.
  • Endeavour Silver Corp. EXK tumbled 9.4% to close at $2.22.
  • Amneal Pharmaceuticals, Inc. AMRX fell 9.4% to close at $2.90.
  • Abeona Therapeutics Inc. ABEO dropped 8.1% to close at $2.26.
  • Mirati Therapeutics, Inc. MRTX fell 7.7% to close at $77.91.
  • Coeur Mining, Inc. CDE fell 7.7% to close at $4.81.
  • Immunomedics, Inc. IMMU shares fell 7.4% to close at $13.26 after interim data from the company's phase 2 study of Sacituzumab Govitecan showed a 29 percent response rate.
  • Precipio, Inc. PRPO dropped 7.1% to close at $2.61.
  • NextCure, Inc. NXTC dropped 5.8% to close at $30.85.
  • Precision BioSciences, Inc. DTIL dropped 5.6% to close at $8.39. Precision BioSciences, named Nicholas Riddle, MB, BChir (MD), PhD, as Vice President, Financial Strategy and Investor Relations.
  • Teekay Corporation TK fell 5.4% to close at $4.00. Teekay Companies will postpone its investor day originally scheduled on Oct 2 to focus on Teekay LNG.
  • Calithera Biosciences, Inc. CALA fell 5% to close at $3.09. Calithera Biosciences announced data from randomized Phase 2 ENTRATA study demonstrate telaglenastat with everolimus improves progression-free survival in renal cell carcinoma at ESMO 2019.

Posted In: BiotechnologyHealth CareMovers From YesterdayTop GainersNewsMovers & ShakersPre-Market OutlookMarketsMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.